Life Sciences»Pharmaceuticals»Therapeutic Area»Respiratory/Pulmonary
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016
| Lowest Prices Guaranteed | Length | Publisher | Published Date | SKU |
|---|---|---|---|---|
| from $2,000 | 56 Pages | Global Markets Direct | August, 2016 | GMD15105998 |
| Lowest Prices Guaranteed | |
| Price | from $2,000 |
|---|---|
| Length | 56 Pages |
| Publisher | Global Markets Direct |
| Published Date | August, 2016 |
| SKU | GMD15105998 |
Table of Contents
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016
Global Markets Direct
- Introduction
- Global Markets Direct Report Coverage
- Severe Acute Respiratory Syndrome (SARS) Overview
- Therapeutics Development
- Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Overview
- Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis
- Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Development by Companies
- Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Investigation by Universities/Institutes
- Severe Acute Respiratory Syndrome (SARS) - Pipeline Products Glance
- Clinical Stage Products
- Early Stage Products
- Severe Acute Respiratory Syndrome (SARS) - Products under Development by Companies
- Severe Acute Respiratory Syndrome (SARS) - Products under Investigation by Universities/Institutes
- Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
- CEL-SCI Corporation
- GeneCure LLC
- Inovio Pharmaceuticals, Inc.
- Nanotherapeutics, Inc.
- Novavax, Inc.
- Phelix Therapeutics, LLC
- Planet Biotechnology Inc.
- Protein Sciences Corporation
- Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- CEL-1000 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- D-3252 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- FDX-000 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INO-4500 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Middle East respiratory syndrome coronavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ML-188 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody for SARS Virus Infections - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RBD-219N1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SARS (virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- severe acute respiratory syndrome vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SSYA-10001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
- Severe Acute Respiratory Syndrome (SARS) - Discontinued Products
- Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
- Featured News & Press Releases
- Oct 19, 2015: Inovio and Partner Advance MERS Vaccine
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016
- Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Development, H2 2016
- Products under Development by Companies, H2 2016
- Products under Investigation by Universities/Institutes, H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corporation, H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by Nanotherapeutics, Inc., H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax, Inc., H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics, LLC, H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by Planet Biotechnology Inc., H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Pipeline by Protein Sciences Corporation, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Assessment by Combination Products, H2 2016
- Number of Products by Stage and Target, H2 2016
- Number of Products by Stage and Mechanism of Action, H2 2016
- Number of Products by Stage and Route of Administration, H2 2016
- Number of Products by Stage and Molecule Type, H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..1), H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..2), H2 2016
- Severe Acute Respiratory Syndrome (SARS) - Discontinued Products, H2 2016
- List of Figures
- Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016
- Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Number of Products by Targets, H2 2016
- Number of Products by Stage and Targets, H2 2016
- Number of Products by Mechanism of Actions, H2 2016
- Number of Products by Stage and Mechanism of Actions, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Molecule Types, H2 2016
- Number of Products by Stage and Molecule Types, H2 2016
Description
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016
Global Markets Direct
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS)
- The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects
- The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS)
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Search inside this report
| Online Download | $2,000 | |
|---|---|---|
| Site License | $4,000 | |
| Global Site License | $6,000 |
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
